

## Refine Search

### Search Results -

Terms	Documents
liposome adj5 (incubat\$ adj3 active)	5

**Database:**

US Pre-Grant Publication Full-Text Database  
US Patents Full-Text Database  
US OCR Full-Text Database  
EPO Abstracts Database  
JPO Abstracts Database  
Derwent World Patents Index  
IBM Technical Disclosure Bulletins

**Search:**

L2

[Refine Search](#)[Recall Text](#)[Clear](#)[Interrupt](#)

### Search History

**DATE:** Monday, July 10, 2006   [Printable Copy](#)   [Create Case](#)

**Set Name**   **Query**  
side by side

**Hit Count**   **Set Name**  
result set

*DB=USPT,EPAB,JPAB,DWPI,TDBD; PLUR=YES; OP=OR*

<u>L2</u>	liposome adj5 (incubat\$ adj3 active)	5	<u>L2</u>
<u>L1</u>	liposome adj5 vip	5	<u>L1</u>

END OF SEARCH HISTORY

[First Hit](#) [Fwd Refs](#)[Previous Doc](#)[Next Doc](#)[Go to Doc#](#)**End of Result Set**

Generate Collection

Print

L17: Entry 1 of 1

File: USPT

Apr 21, 1998

DOCUMENT-IDENTIFIER: US 5741804 A

TITLE: Substituted benzimidazoles which inhibit platelet aggregation

Brief Summary Text (13):

In another aspect, this invention provides a method for inhibiting reocclusion of an artery or vein in a mammal following fibrinolytic therapy, which comprises internally administering an effective amount of a fibrinolytic agent and a compound of formula (I). This invention is also a method for treating stroke, transient ischemia attacks, myocardial infarction, or atherosclerosis.

Brief Summary Text (76):

[5-(4-(aminoiminomethyl)benzoylamino]benzimidazole-2-amino-N-acetic acid;

Brief Summary Text (77):

[5-(4-aminoiminomethyl)benzoylamino]benzimidazole-2-amino-N-propanoic acid;

Brief Summary Text (78):

[5-(4-aminoiminomethyl)benzoylamino]benzimidazole-2-propanoic acid;

Brief Summary Text (79):

[5-(4-aminomethyl)benzoylamino]benzimidazole-2-amino-N-acetic acid;

Brief Summary Text (81):

1-N-benzyl-[6-(4-aminoiminomethyl)benzoylamino]benzimidazole-2-propanoi c acid;

Brief Summary Text (82):

1-N-benzyl-[5-(4-aminoiminomethyl)benzoylamino]benzimidazole-2-propanoi c acid; and

Brief Summary Text (83):

1-N-phenethyl-[5-(4-aminoiminomethyl)benzoylamino]benzimidazole-2-propa noic acid;

Brief Summary Text (85):

The most preferred compound of this invention is [5-(4-aminoiminomethyl)benzoylamino]benzimidazole-2-propanoic acid or a pharmaceutically acceptable salt thereof.

Detailed Description Text (3):

[5-(4-Aminoiminomethyl)benzoylamino]benzimidazole-2-amino-N-acetic Acid

Detailed Description Text (8):

(iii) [5-(4-Cbz-aminoiminomethyl)benzoylamino]benzimidazole-2-amino-N-acetate, methyl ester

Detailed Description Text (10):

(iv) [5-(4-Aminoiminomethyl)benzoylamino]benzimidazole-2-amino-N-acetate methyl ester, acetate salt

Detailed Description Text (12):

(v) [5-(4-Aminoiminomethyl)benzoylamino]benzimidazole-2-amino-N-acetic acid, trifluoroacetic acid salt

Detailed Description Text (15):

[5-(4-Aminoiminomethyl)benzoylamino]benzimidazole-2-amino-N-propionic Acid

Detailed Description Text (22):

(iv) [5-(4-Cbz-aminoiminomethyl)benzoylamino]benzimidazole-2-amino-N-propanoate, methyl ester

Detailed Description Text (24):

(v) [5-(4-Aminoiminomethyl)benzoylamino]benzimidazole-2-amino-N-propanoate, methyl ester, acetate salt

Detailed Description Text (26):

(vi) [5-(4-Aminoiminomethyl)benzoylamino]benzimidazole-2-amino-N-propanoic acid, trifluoroacetic acid salt

Detailed Description Text (41):

[5-(4-Aminoiminomethyl)benzoylamino]benzimidazole-2-propanoic Acid

Detailed Description Text (46):

(iii) [5-(4-Cbz-aminoiminomethyl)benzoylamino]benzimidazole-2-propanoate, methyl ester

Detailed Description Text (48):

(iv) [5-(4-Aminoiminomethyl)benzoylamino]benzimidazole-2-propanoate methyl ester, acetate salt

Detailed Description Text (50):

(v) [5-(4-Aminoiminomethyl)benzoylamino]benzimidazole-2-propanoic acid, trifluoroacetic acid salt

Detailed Description Text (53):

[5-(4-Aminomethyl)benzoylamino]benzimidazole-2-amino-N-acetic Acid

Detailed Description Text (54):

(i) [5-(4-Boc-aminomethyl)benzoylamino]benzimidazole-2-amino-N-acetate, methyl ester

Detailed Description Text (56):

(ii) [5-(4-Aminomethyl)benzoylamino]benzimidazole-2-N-amino-acetic acid, trifluoroacetic acid salt

Detailed Description Text (59):

1-N-Benzyl-[5-(4-aminoiminomethyl)benzoylamino]benzimidazole-2-propanoic Acid (i)  
1-N-Benzyl-5-nitrobenzimidazole-2-propanoate, methyl ester

Detailed Description Text (63):

(iii) 1-N-Benzyl-[5-(4-Cbz-aminoiminomethyl)benzoylamino]benzimidazole-2-propanoate, methyl ester

Detailed Description Text (65):

(iv) 1-N-Benzyl-[5-(4-aminoiminomethyl)benzoylamino]benzimidazole-2-propanoate, methyl ester, acetate salt

Detailed Description Text (67):

(v) 1-N-Benzyl-[5-(4-aminoiminomethyl)benzoylamino]benzimidazole-2-propanoic acid, trifluoroacetic acid salt

Detailed Description Text (70):

1-N-Benzyl-[6-(4-aminoiminomethyl)benzoylamino]benzimidazole-2-propanoic Acid

Detailed Description Text (73):

(ii) 1-N-Benzyl-[6-(4-Cbz-aminoiminomethyl)benzoylamino]benzimidazole-2-propanoate, methyl ester

Detailed Description Text (75):

(iii) 1-N-Benzyl-[6-(4-aminoiminomethyl)benzoylamino]benzimidazole-2-propanoate, methyl ester, acetate salt

Detailed Description Text (77):

(iv) 1-N-Benzyl-[6-(4-aminoiminomethyl)benzoylamino]benzimidazole-2-propanoic acid, trifluoroacetic acid salt

Detailed Description Text (80):

1-N-Phenethyl-[5-(4-aminoiminomethyl)benzoylamino]benzimidazole-2-propanoic Acid

Detailed Description Text (85):

(iii) 1-N-Phenethyl-[5-(4-Cbz-aminoiminomethyl)benzoylamino]benzimidazole-2-propanoate, methyl ester

Detailed Description Text (87):

(iv) 1-N-Phenethyl-[5-(4-aminoiminomethyl)benzoylamino]benzimidazole-2-propanoate, methyl ester, acetate salt

Detailed Description Text (89):

(v) 1-N-Phenethyl-[5-(4-aminoiminomethyl)benzoylamino]benzimidazole-2-propanoic acid, trifluoroacetic acid salt

## CLAIMS:

2. A compound which is [5-(4-aminoiminomethyl)-benzoylamino]benzimidazole-2-propanoic acid or a pharmaceutically acceptable salt thereof.

3. A compound which is:

[5-(4-(aminoiminomethyl)benzoylamino]benzimidazole-2-amino-N-acetic acid;

[5-(4-aminoiminomethyl)benzoylamino]benzimidazole-2-amino-N-propanoic acid;

[5-(4-aminomethyl)benzoylamino]benzimidazole-2-amino-N-acetic acid;

[5-(4-aminoiminomethyl)phenylaminocarbonyl]benzimidazole-2-amino-N-acetic acid;

1-N-benzyl-[6-(4-aminoiminomethyl)benzoylamino]benzimidazole-2-propanoic acid;

1-N-benzyl-[5-(4-aminoiminomethyl)benzoylamino]benzimidazole-2-propanoic acid; or

1-N-phenethyl-[5-(4-aminoiminomethyl)benzoylamino]benzimidazole-2-propanoic acid;

or a pharmaceutically acceptable salt thereof.

[Previous Doc](#)

[Next Doc](#)

[Go to Doc#](#)

## Hit List

First Hit

Clear

Generate Collection

Print

Fwd Refs

Bkwd Refs

Generate OACS

Search Results - Record(s) 1 through 1 of 1 returned.

☐ 1. Document ID: US 5741804 A

L17: Entry 1 of 1

File: USPT

Apr 21, 1998

US-PAT-NO: 5741804

DOCUMENT-IDENTIFIER: US 5741804 A

TITLE: Substituted benzimazoles which inhibit platelet aggregation

DATE-ISSUED: April 21, 1998

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Keenan; Richard McCulloch	Malvern	PA		
Miller; William Henry	Schwenksville	PA		

US-CL-CURRENT: 514/394; 514/322, 514/388, 514/419, 546/199, 548/308.7, 548/310.1, 548/494

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	RMC	Draw D
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	-----	--------

Clear

Generate Collection

Print

Fwd Refs

Bkwd Refs

Generate OACS

Terms

Documents

L16 and (arteriosclerosis or atherosclerosis)

1

Display Format:

Change Format

[Previous Page](#)[Next Page](#)[Go to Doc#](#)

[First Hit](#) [Fwd Refs](#)[Previous Doc](#)[Next Doc](#)[Go to Doc#](#)

Generate Collection

Print

L2: Entry 1 of 5

File: USPT

Nov 11, 2003

DOCUMENT-IDENTIFIER: US 6645522 B2

TITLE: Erythropoietin liposomal dispersion

Brief Summary Text (14):

In accordance with the invention, the composition comprises single bilayered liposomes made by preparing an alcoholic solution of the lipidic phase and injecting the solution under pressure into an aqueous buffer solution contained in a high speed homogenizer. The liposomes thus prepared are incubated with the erythropoietin active ingredient to form the liposomal dispersion of the invention.

Brief Summary Text (27):

The liposome-based compositions of the present invention are prepared by applying the methods known in the art for manufacturing liposome compositions described in EP 253619, hereby incorporated by reference. In this method single bilayered liposomes are prepared by preparing an ethanolic solution of a phospholipid and the active ingredient and injecting the solution under pressure into an aqueous buffer solution contained in a high speed homogenizer. The liposomes are formed spontaneously providing liposomes having a diameter of less than 1 .mu.m. In particular, in accordance with the method of the present invention, the liposomes are manufactured by forming an aqueous buffer solution in purified water. Separately, the lecithin, cholesterol and charged lipid component are dissolved in an alcoholic solution such as ethanol. The aqueous solution is connected to a high performance homogenizer to effect circulation and the alcoholic solution is directly injected into the homogenizer. Liposomes of less than 1 .mu.m are formed spontaneously. The liposomes thus formed are then incubated with the EPO active ingredient to form a liposomal dispersion of the invention.

[Previous Doc](#)[Next Doc](#)[Go to Doc#](#)

[First Hit](#) [Fwd Refs](#)[Previous Doc](#)[Next Doc](#)[Go to Doc#](#)

Generate Collection

Print

L2: Entry 2 of 5

File: USPT

Feb 19, 2002

DOCUMENT-IDENTIFIER: US 6348214 B1

TITLE: Materials and methods for making improved liposome compositions

Brief Summary Text (19):

The invention further provides improved acoustic diagnostic products which have surprising acoustic reflectivity properties despite the fact that they are less than 1000 nm and even 300 nm in average diameter. The results using the liposomes less than 300 nm in diameter are particularly surprising in light of the teachings of the art that such liposomes should range from 0.8 to 3.0 microns in diameter. Specifically, the invention provides methods for the preparation and use of multilamellar diagnostic liposomes having an average diameter of less than about 1000 nm and particularly less than about 500 nm for improved imaging using acoustic reflectivity techniques. Herein, acoustic reflectivity, echo-reflectivity, and ultrasonic imaging are used with essentially the same meaning. The method of the invention comprises the steps of mixing a combination of lipids wherein at least one lipid component is conjugated to a water soluble polymer, forming and obtaining liposomes from the mixed combination of lipids, incubating the liposomes with a biologically active amphipathic compound, and forming multilamellar liposomes having an average diameter of about less than 1000 nm. According to a preferred embodiment of the invention, the multilamellar liposomes are formed by carrying out a lyophilization method. In a preferred embodiment, the liposomes first formed from the mixture of lipids have an average diameter of about less than 300 nm and in another embodiment these liposomes are obtained by extrusion. A preferred multilamellar liposome of the invention has an average diameter of about less than 800 nm, but most preferably has an average diameter of less than about 300 nm. In a preferred embodiment, the water soluble polymer is PEG. Biologically active compounds of the invention include those which are capable of forming .alpha.- or .pi.-helical domains and preferably are chosen from members of the VIP/GRF family of peptides. The most preferred biologically active compound of the invention is VIP. While not intending to be bound by any theory of their invention, it is believed that the incorporation of a water-soluble polymer such as PEG into the multivesicular liposomes may make them more capable of reflecting acoustic energy in spite of their relatively small size. While it is not completely understood why this might be the case, one possibility is that the presence of the water-soluble polymer acts to separate the walls of the multiple liposome vesicles making up a single multivesicular liposome and thus rendering that liposome better capable of reflecting acoustic radiation.

Detailed Description Text (3):

In contrast to prior art methods which frequently include the step of extruding peptide-containing liposomes through membranes and filters to obtain liposomes of a desired size, the liposomes according to the present invention are obtained having a diameter of less than 300 nm prior to being contacted with the active compound ingredient. Liposomes of this size may be obtained using an extrusion step which modifies liposomes, thereby reducing the size of the liposomes to a preferred average diameter prior to being incubated with the biologically active compound. Alternatively, liposomes of the desired size may be selected using techniques such as filtration or other size selection techniques. While the size-selected liposomes of the invention should have an average diameter of less than about 300 nm, it is preferred that they are selected to have an average diameter of less than about 200

nm with an average diameter of less than about 100 nm being particularly preferred. When the biologically active liposome product is a unilamellar liposome, it preferably is selected to have an average diameter of less than about 200 nm. The most preferred unilamellar liposomes of the invention have an average diameter of less than about 100 nm. It is understood, however, that multivesicular liposomes of the invention derived from smaller unilamellar liposomes will generally be larger and may have an average diameter of about less than 1000 nm. Preferred multivesicular liposomes of the invention have an average diameter of less than about 800 nm, and less than about 500 nm while most preferred multivesicular liposomes of the invention have an average diameter of less than about 300 nm.

[Previous Doc](#)[Next Doc](#)[Go to Doc#](#)



[First Hit](#)      [Previous Doc](#)      [Next Doc](#)      [Go to Doc#](#)  
**End of Result Set**

☐ [Generate Collection](#) [Print](#)

L2: Entry 5 of 5

File: DWPI

Oct 2, 1997

DERWENT-ACC-NO: 1997-489350

DERWENT-WEEK: 199807

COPYRIGHT 2006 DERWENT INFORMATION LTD

TITLE: Preparation of echogenic liposome products - which contain biologically active amphipathic compound, such as vasoactive intestinal peptide, in active conformation

INVENTOR: MCPHERSON, D D; MURER, S E ; ONYUKSEL, H ; RUBINSTEIN, I

PATENT-ASSIGNEE: UNIV ILLINOIS FOUND (UNII), UNIV NORTHWESTERN (NOUN)

PRIORITY-DATA: 1996US-0014363 (March 28, 1996)

[Search Selected](#)[Search ALL](#)[Clear](#)

## PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
<input type="checkbox"/> <a href="#">WO 9735560 A1</a>	October 2, 1997	E	048	A61K009/127
<input type="checkbox"/> <a href="#">AU 9725492 A</a>	October 17, 1997		000	A61K009/127

DESIGNATED-STATES: AU CA JP US AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

CITED-DOCUMENTS:JP 82311; US 4529561 ; US 5230882

## APPLICATION-DATA:

PUB-NO	APPL-DATE	APPL-NO	DESCRIPTOR
WO 9735560A1	March 28, 1997	1997WO-US04939	
AU 9725492A	March 28, 1997	1997AU-0025492	
AU 9725492A		WO 9735560	Based on

INT-CL (IPC): [A61 K 9/127](#)

RELATED-ACC-NO: 1997-489351

ABSTRACTED-PUB-NO: WO 9735560A

## BASIC-ABSTRACT:

Preparation of an echogenic liposome diagnostic product, comprising a biologically active amphipathic compound (which is capable of permitting specific targeting within a recipient) in association with a liposome, comprises: (a) mixing a combination of lipids which includes at least one lipid component covalently bonded to a water-soluble polymer; (b) forming and obtaining liposomes from the

combination of lipids; (c) incubating the liposomes with a biologically active amphipathic compound so that the compound becomes associated with the liposomes in an active conformation; and (d) forming multilamellar liposome products with an average diameter of less than 1000 nm.

USE - The liposome product is used in diagnostic methods comprising administering the liposome to a target tissue, and detecting the uptake of the liposome at the target tissue by acoustic reflectivity (claimed). The target tissue is preferably a tumour. The biologically active amphipathic compounds are vasoactive intestinal peptide (VIP) and growth hormone releasing factor (GRF), which may be used in treatment of, e.g., skin wrinkling, skin aging, wounds, inflammatory bowel disorder, constipation, Hirschprung's disease, achalasia, infantile hypertrophic pyloric stenosis, asthma, hypertension, scleroderma, myocardial ischaemia, impotence, baldness, Alzheimer's disease or allergies. VIP may be used in preventing apoptosis or organ/tissue rejection.

ADVANTAGE- The active compound attains, and is maintained in, an active or more active conformation than the compound in an aqueous environment. The process can overcome problems associated with prior art liposomal formulations, such as uptake by the reticuloendothelial system, degradation of the compound or delivery of the compound in an inactive conformation.

ABSTRACTED-PUB-NO: WO 9735560A  
EQUIVALENT-ABSTRACTS:

CHOSEN-DRAWING: Dwg.0/6

DERWENT-CLASS: B04 B07  
CPI-CODES: B11-C09; B12-K04C1; B12-M11F; B14-E10C; B14-K01A; B14-N17B; B14-R01; B14-R02;

[Previous Doc](#)

[Next Doc](#)

[Go to Doc#](#)

## Refine Search

### Search Results -

Terms	Documents
L16 and (arteriosclerosis or atherosclerosis)	1

Database:

US Pre-Grant Publication Full-Text Database  
 US Patents Full-Text Database  
 US OCR Full-Text Database  
 EPO Abstracts Database  
 JPO Abstracts Database  
 Derwent World Patents Index  
 IBM Technical Disclosure Bulletins

Search:

L17

Refine/Search

Recall Text

Clear

Interrupt

### Search History

 DATE: Monday, July 10, 2006    [Printable Copy](#)    [Create Case](#)

<u>Set</u> <u>Name</u>	<u>Query</u>	<u>Hit</u> <u>Count</u>	<u>Set</u> <u>Name</u> result set
<i>DB=USPT,EPAB,JPAB,DWPI,TDBD; PLUR=YES; OP=OR</i>			
<u>L17</u>	L16 and (arteriosclerosis or atherosclerosis)	1	<u>L17</u>
<u>L16</u>	(benzoyl\$benzimidazole)	49	<u>L16</u>
<u>L15</u>	liposome same (\$benzimidazole) same (cholesterol)	5	<u>L15</u>
<u>L14</u>	L13 and 424/450.ccls.	8	<u>L14</u>
<u>L13</u>	liposome adj10 (smooth adj1 muscle)	50	<u>L13</u>
<u>L12</u>	liposome adj10 (smotth adj1 muscle)	0	<u>L12</u>
<u>L11</u>	liposome adj10 (arteriosclerosis or atherosclerosis)	35	<u>L11</u>
<u>L10</u>	L9 and 424/450.ccls.	38	<u>L10</u>
<u>L9</u>	liposome adj5 (vascular or arteriosclerosis or atherosclerosis)	110	<u>L9</u>
<u>L8</u>	liposome same (vascular or arteriosclerosis or atherosclerosis)	776	<u>L8</u>
<u>L7</u>	liposome and (\$benzimidazole) same (vascular or arteriosclerosis or atherosclerosis)	19	<u>L7</u>
	liposome and (\$benzimidazole) same (vascular or arteriosclerosis or		

<u>L6</u>	atherosclerosis)	19	<u>L6</u>
<u>L5</u>	liposome same \$benzimidazole same (vascular or arteriosclerosis or atherosclerosis)	1	<u>L5</u>
<u>L4</u>	(liposome same \$benzimidazole) same (smooth adj1 muscle)	1	<u>L4</u>
<u>L3</u>	(liposome same benzimidazole) same (smooth adj1 muscle)	1	<u>L3</u>
<u>L2</u>	(liposome same benzimidazole) and (vascular or arteriosclerosis or atherosclerosis)	11	<u>L2</u>
<u>L1</u>	liposome same benzimidazole same (vascular or arteriosclerosis or atherosclerosis)	1	<u>L1</u>

END OF SEARCH HISTORY

## Refine Search

---

### Search Results -

Terms	Documents
L13 and (424/450).ccls.	8

Database:

US Pre-Grant Publication Full-Text Database  
 US Patents Full-Text Database  
 US OCR Full-Text Database  
 EPO Abstracts Database  
 JPO Abstracts Database  
 Derwent World Patents Index  
 IBM Technical Disclosure Bulletins

Search:

L14






---

### Search History

---

 DATE: Monday, July 10, 2006    [Printable Copy](#)    [Create Case](#)

<u>Set Name</u> side by side	<u>Query</u>	<u>Hit Count</u>	<u>Set Name</u> result set
	<i>DB=USPT,EPAB,JPAB,DWPI,TDBD; PLUR=YES; OP=OR</i>		
<u>L14</u>	L13 and 424/450.ccls.	8	<u>L14</u>
<u>L13</u>	liposome adj10 (smooth adj1 muscle)	50	<u>L13</u>
<u>L12</u>	liposome adj10 (smotth adj1 muscle)	0	<u>L12</u>
<u>L11</u>	liposome adj10 (arteriosclerosis or atherosclerosis)	35	<u>L11</u>
<u>L10</u>	L9 and 424/450.ccls.	38	<u>L10</u>
<u>L9</u>	liposome adj5 (vascular or arteriosclerosis or atherosclerosis)	110	<u>L9</u>
<u>L8</u>	liposome same (vascular or arteriosclerosis or atherosclerosis)	776	<u>L8</u>
<u>L7</u>	liposome and (\$benzimidazole) same (vascular or arteriosclerosis or atherosclerosis)	19	<u>L7</u>
<u>L6</u>	liposome and (\$benzimidazole) same (vascular or arteriosclerosis or atherosclerosis)	19	<u>L6</u>
<u>L5</u>	liposome same \$benzimidazole same (vascular or arteriosclerosis or atherosclerosis)	1	<u>L5</u>

<u>L4</u>	(liposome same \$benzimidazole) same (smooth adj1 muscle)	1	<u>L4</u>
<u>L3</u>	(liposome same benzimidazole) same (smooth adj1 muscle)	1	<u>L3</u>
<u>L2</u>	(liposome same benzimidazole) and (vascular or arteriosclerosis or atherosclerosis)	11	<u>L2</u>
<u>L1</u>	liposome same benzimidazole same (vascular or arteriosclerosis or atherosclerosis)	1	<u>L1</u>

END OF SEARCH HISTORY

First Hit      Previous Doc      Next Doc      Go to Doc#



Generate Collection

Print

L11: Entry 31 of 35

File: DWPI

Aug 19, 1997

DERWENT-ACC-NO: 1997-466196

DERWENT-WEEK: 199743

COPYRIGHT 2006 DERWENT INFORMATION LTD

TITLE: Liposome compositions comprising ribozymes - useful for treating arteriosclerosis and hyper-lipoproteinaemia

PATENT-ASSIGNEE: KANADA Y (KANAI), MORISHITA R (MORII), OGIWARA T (OGIWI)

PRIORITY-DATA: 1996JP-0022879 (February 8, 1996)

Search Selected

Search ALL

Clear

## PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
<input type="checkbox"/> JP 09216825 A	August 19, 1997		006	A61K031/70

## APPLICATION-DATA:

PUB-NO	APPL-DATE	APPL-NO	DESCRIPTOR
JP 09216825A	February 8, 1996	1996JP-0022879	

INT-CL (IPC): A61 K 9/127; A61 K 31/70; A61 K 48/00; C07 H 21/02; C12 N 9/22; C12 N 15/09

ABSTRACTED-PUB-NO: JP 09216825A

## BASIC-ABSTRACT:

Liposome compositions comprise ribozymes. Also claimed is a ribozyme represented by the RNA sequence of formula (I) or its analogue. X = nucleotide; Xn, Xm = stem-and-loop formed by oligonucleotides, in which 3'-(Y)CA(Z)-5' works as a complementary sequence for the mRNA of apoprotein (a); and (Y), (Z) = nucleotide comprising 3 bases or longer.

USE - The liposome compositions (which may be those of LUV, MLV or SUV prepared using reverse-phase evaporation, ether diffusion or surface activation) is useful for preventing or treating arteriosclerosis or hyperlipoproteinemia.

ADVANTAGE - By treating the liposome composition with Sendai virus, the uptake of ribozymes into the cells or tissues of the affected part is promoted. The ribozymes specifically act on the apoprotein (a) without any influence on plasminogen.

ABSTRACTED-PUB-NO: JP 09216825A

## EQUIVALENT-ABSTRACTS:

CHOSEN-DRAWING: Dwg.0/0

DERWENT-CLASS: B04 D16

CPI-CODES: B04-E01; B12-M11F; B14-F06; B14-F07; B14-F11; D05-H12D4;

[Previous Doc](#)

[Next Doc](#)

[Go to Doc#](#)



[First Hit](#) [Fwd Refs](#)[Previous Doc](#)[Next Doc](#)[Go to Doc#](#)

Generate Collection

Print

L14: Entry 6 of 8

File: USPT

Aug 26, 1997

US-PAT-NO: 5660855

DOCUMENT-IDENTIFIER: US 5660855 A

TITLE: Lipid constructs for targeting to vascular smooth muscle tissue

DATE-ISSUED: August 26, 1997

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Male-Brune; Roxanne	Hillsborough	NC		

US-CL-CURRENT: [424/450](#); [514/24](#), [514/9](#)

## CLAIMS:

I claim:

1. A method of targeting vascular smooth muscle tissue by delivering to an artery a lipid construct containing a therapeutic or imaging agent wherein said construct comprises an aminomannose derivatized cholesterol.
2. The method as recited in claim 1 wherein the aminomannose derivatized cholesterol comprises 6-(cholest-5-en-3.beta.-yloxy)hexyl-6-amino-6-deoxy-1-thio-.alpha.-D-manno pyranoside.
3. The method of claim 2 wherein the therapeutic agent comprises an agent which prevents neointima formation.
4. The method of claim 3 wherein the method of delivering said construct comprises a percutaneous transluminal coronary angioplasty procedure.
5. The method of claim 2 wherein the method of delivering said construct comprises a percutaneous transluminal coronary angioplasty procedure.
6. The method of claim 1 wherein the therapeutic agent comprises an agent which prevents neointima formation.
7. The method of claim 3 wherein the method of delivering said construct comprises a percutaneous transluminal coronary angioplasty procedure.
8. The method of claim 1 wherein the method of delivering said construct comprises a percutaneous transluminal coronary angioplasty procedure.

[Previous Doc](#)[Next Doc](#)[Go to Doc#](#)

## Hit List

First Hit

Clear

Generate Collection

Print

Fwd Refs

Bkwd Refs

Generate OACS

Search Results - Record(s) 1 through 11 of 11 returned.

☐ 1. Document ID: US 6001335 A

L2: Entry 1 of 11

File: USPT

Dec 14, 1999

US-PAT-NO: 6001335

DOCUMENT-IDENTIFIER: US 6001335 A

\*\* See image for Certificate of Correction \*\*

TITLE: Contrasting agents for ultrasonic imaging and methods for preparing the same

DATE-ISSUED: December 14, 1999

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Unger; Evan C.	Tucson	AZ		

US-CL-CURRENT: 424/9.52; 264/4, 264/4.1, 424/450, 424/9.51, 427/2.14, 427/213.3,  
428/402.2

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	FIGS	Drawings
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 2. Document ID: US 5985246 A

L2: Entry 2 of 11

File: USPT

Nov 16, 1999

US-PAT-NO: 5985246

DOCUMENT-IDENTIFIER: US 5985246 A

\*\* See image for Certificate of Correction \*\*

TITLE: Contrast agents for ultrasonic imaging and methods for preparing the same

DATE-ISSUED: November 16, 1999

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Unger; Evan C.	Tucson	AZ		

US-CL-CURRENT: 424/9.51; 264/4, 424/450, 424/9.52, 427/213.3, 428/402.2

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	FIGS	Drawings
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 3. Document ID: US 5571497 A

L2: Entry 3 of 11

File: USPT

Nov 5, 1996

US-PAT-NO: 5571497

DOCUMENT-IDENTIFIER: US 5571497 A

**\*\* See image for Certificate of Correction \*\***

TITLE: Liposomes as contrast agents for ultrasonic imaging and apparatus and methods for preparing the same

DATE-ISSUED: November 5, 1996

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Unger; Evan C.	Tucson	AZ		

US-CL-CURRENT: 423/87; 205/586

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	FIGS	Drawings
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 4. Document ID: US 5456901 A

L2: Entry 4 of 11

File: USPT

Oct 10, 1995

US-PAT-NO: 5456901

DOCUMENT-IDENTIFIER: US 5456901 A

**\*\* See image for Certificate of Correction \*\***

TITLE: Liposomes as contrast agents for ultrasonic imaging

DATE-ISSUED: October 10, 1995

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Unger; Evan C.	Tucson	AZ	85749	

US-CL-CURRENT: 424/9.51; 424/450, 600/458

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	FIGS	Drawings
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 5. Document ID: US 5352435 A

L2: Entry 5 of 11

File: USPT

Oct 4, 1994

US-PAT-NO: 5352435

DOCUMENT-IDENTIFIER: US 5352435 A

**\*\* See image for Certificate of Correction \*\***

TITLE: Ionophore containing liposomes for ultrasound imaging

DATE-ISSUED: October 4, 1994

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Unger; Evan C.	Tucson	AZ	85749	

US-CL-CURRENT: 424/9.51; 424/450, 600/448

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	FIGS	Draw D
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	--------

☐ 6. Document ID: US 5334381 A

L2: Entry 6 of 11

File: USPT

Aug 2, 1994

US-PAT-NO: 5334381

DOCUMENT-IDENTIFIER: US 5334381 A

**\*\* See image for Certificate of Correction \*\***

TITLE: Liposomes as contrast agents for ultrasonic imaging and methods for preparing the same

DATE-ISSUED: August 2, 1994

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Unger; Evan C.	Tucson	AZ	85749	

US-CL-CURRENT: 424/9.51; 264/4.1, 264/4.3, 424/450, 428/402, 600/431

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	FIGS	Draw D
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	--------

☐ 7. Document ID: US 5230882 A

L2: Entry 7 of 11

File: USPT

Jul 27, 1993

US-PAT-NO: 5230882

DOCUMENT-IDENTIFIER: US 5230882 A

**\*\* See image for Certificate of Correction \*\***

TITLE: Liposomes as contrast agents for ultrasonic imaging and methods for preparing the same

DATE-ISSUED: July 27, 1993

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Unger; Evan C.	Tucson	AZ	85749	

US-CL-CURRENT: 424/9.51; 424/450, 514/150, 514/546, 600/458

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	FIGS	Drawings
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 8. Document ID: US 5123414 A

L2: Entry 8 of 11

File: USPT

Jun 23, 1992

US-PAT-NO: 5123414

DOCUMENT-IDENTIFIER: US 5123414 A

**\*\* See image for Certificate of Correction \*\***

TITLE: Liposomes as contrast agents for ultrasonic imaging and methods for preparing the same

DATE-ISSUED: June 23, 1992

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Unger; Evan C.	Tucson	AZ	85749	

US-CL-CURRENT: 600/431; 264/4.1, 264/4.3, 424/450, 424/9.51

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	FIGS	Drawings
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 9. Document ID: US 5088499 A

L2: Entry 9 of 11

File: USPT

Feb 18, 1992

US-PAT-NO: 5088499

DOCUMENT-IDENTIFIER: US 5088499 A

**\*\* See image for Certificate of Correction \*\***

TITLE: Liposomes as contrast agents for ultrasonic imaging and methods for preparing the same

DATE-ISSUED: February 18, 1992

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Unger; Evan C.	Tucson	AZ	85749	

US-CL-CURRENT: 424/9.51; 424/44, 424/450, 436/829

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	FIGS	Drawings
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 10. Document ID: JP 2004115397 A

L2: Entry 10 of 11

File: JPAB

Apr 15, 2004

PUB-NO: JP02004115397A

DOCUMENT-IDENTIFIER: JP 2004115397 A

TITLE: LIPOSOME COMPRISING THERAPEUTIC AGENT FOR VASCULAR DISEASE

PUBN-DATE: April 15, 2004

## INVENTOR-INFORMATION:

NAME

COUNTRY

AIKAWA, KAZUHIRO

INT-CL (IPC): A61 K 9/127; A61 K 31/4184; A61 K 45/00; A61 K 47/24; A61 P 9/00;  
A61 P 9/10; A61 P 43/00

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	RMK	Draw D
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	-----	--------

☐ 11. Document ID: EP 1402884 B1, EP 1402884 A1, JP 2004115397 A, US 20040120999 A1

L2: Entry 11 of 11

File: DWPI

May 31, 2006

DERWENT-ACC-NO: 2004-285129

DERWENT-WEEK: 200637

COPYRIGHT 2006 DERWENT INFORMATION LTD

TITLE: Liposome useful as a medicament for treating vascular diseases caused by abnormal proliferation of vascular smooth muscle cells comprises active ingredient as membrane component

INVENTOR: AIKAWA, K

PRIORITY-DATA: 2002JP-0278287 (September 25, 2002)

## PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
<u>EP 1402884 B1</u>	May 31, 2006	E	000	A61K009/127
<u>EP 1402884 A1</u>	March 31, 2004	E	015	A61K009/127
<u>JP 2004115397 A</u>	April 15, 2004		009	A61K009/127
<u>US 20040120999 A1</u>	June 24, 2004		000	A61K031/4184

INT-CL (IPC): A61 K 9/127; A61 K 31/4164; A61 K 31/4184; A61 K 45/00; A61 K 47/24;  
A61 P 9/00; A61 P 9/10; A61 P 43/00

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	RMK	Draw D
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	-----	--------

[Clear](#)[Generate Collection](#)[Print](#)[Fwd Refs](#)[Bkwd Refs](#)[Generate OACS](#)

Terms

(liposome same benzimidazole) and (vascular or arteriosclerosis or atherosclerosis)

Documents

11

**Display Format:**  **Change Format**

[Previous Page](#)

[Next Page](#)

[Go to Doc#](#)

[First Hit](#) [Fwd Refs](#)[Previous Doc](#)[Next Doc](#)[Go to Doc#](#)

Generate Collection

Print

L6: Entry 7 of 19

File: USPT

Nov 9, 2004

DOCUMENT-IDENTIFIER: US 6815455 B1

TITLE: Benzimidazole compounds and drugs containing the same

Abstract Text (1):

A benzimidazole compound or a salt thereof which has an inhibitory action of foaming of macrophages and is useful as an active ingredient of a medicament for preventive and/or therapeutic treatment of arteriosclerosis, which is represented by the formula (I): ##STR1##

Brief Summary Text (9):

The compounds represented by the formula (I) according to the present invention have an inhibitory action against the foaming of macrophages independent from the ACAT inhibitory activity, and achieve remarkable effects in preventive and/or flit therapeutic treatment of arteriosclerosis based on the action. As benzimidazole compounds, available compounds include those known as active ingredients of medicaments for other applications (for example, the compounds of International Patent Publication W095/34304) or those known as synthetic intermediates for drugs, agricultural chemicals or the like (for example, Chim. Chronika., Vol. 9(3), 239-246 (1980)). However, as demonstrated in the examples, the benzimidazole compounds known so far fail to inhibit the foaming of macrophages, and specific action of the compounds of the present invention are not suggested in view of these compounds.

Detailed Description Text (315):

15-Week old female ICR mice (Nippon SLC) were subjected to bleeding by cutting off their cervicalis, and Hanks buffer (Nippon Seiyaku) was injected into their peritoneal cavities. After abdominal regions of the mice were massaged, the buffer was recovered immediately, and then the resulting buffer was centrifuged at 1,000 r.p.m. for five minutes to collect peritoneal macrophages. Then, the collected macrophages were suspended in GTI medium (Wako Pure Chemical Industries), and inoculated onto a 24-well microtiter plate. After the macrophages were cultivated at 37.degree. C. under 5% CO.sub.2 for two hours, the culture medium was changed with Dulbecco Modified Eagle Medium (MEM, Nippon Seiyaku). The macrophages were further cultivated at 37.degree. C. under 5% CO.sub.2 for 16 hours, and then a test compound and liposomes were added to the culture. 1) Test compound: dissolved in DMSO (Wako Pure Chemical Industries), 2) Liposomes: PC/PS/DCP/CHOL=50/50/10/75; (nmol)

Detailed Description Text (328):

The benzimidazole derivatives of the present invention have an action of suppressing the foaming of macrophages, and are useful as active ingredients of medicaments for preventive and/or therapeutic treatment of arteriosclerosis or medicaments for preventive and/or therapeutic treatment of hyperlipidemia. Further, they are also useful as additives for silver halide photosensitive materials or for the production of liquid crystals.

[Previous Doc](#)[Next Doc](#)[Go to Doc#](#)



[First Hit](#) [Fwd Refs](#)[Previous Doc](#)[Next Doc](#)[Go to Doc#](#)

Generate Collection

Print

L6: Entry 9 of 19

File: USPT

Feb 17, 2004

DOCUMENT-IDENTIFIER: US 6693101 B2

TITLE: .alpha.v integrin receptor antagonists

Brief Summary Text (16):

The .alpha.v.beta.3 integrin receptor recognizes the Arg-Gly-Asp (RGD) tripeptide sequence in its cognate matrix and cell surface glycoproteins (see J. Samanen, et al., "Vascular Indications for Integrin .alpha.v Antagonists," Curr. Pharmaceut. Design 3: 545-584 (1997)). A benzazepine nucleus has been employed among others by Genentech and SmithKline Beecham as a conformationally constrained Gly-Asp mimetic to elaborate nonpeptide .alpha.v.beta.3 integrin receptor antagonists substituted at the N-terminus with heterocyclic arginine mimetics (see R. M. Keenan et al., "Discovery of Potent Nonpeptide Vitronectin Receptor (.alpha.v.beta.3) Antagonists," J. Med. Chem. 40: 2289-2292 (1997); R. M. Keenan et al., "Benzimidazole Derivatives As Arginine Mimetics in 1,4-Benzodiazepine Nonpeptide Vitronectin Receptor (.alpha.v.beta.3) Antagonists," Bioorg. Med. Chem. Lett. 8: 3165-3170 (1998); and R. M. Keenan et al., "Discovery of an Imidazopyridine-Containing 1,4-Benzodiazepine Nonpeptide Vitronectin Receptor (.alpha.v.beta.3) Antagonist With Efficacy in a Restenosis Model," Bioorg. Med. Chem. Lett. 8: 3171-3176 (1998). Patents assigned to SmithKline Beecham that disclose such benzazepine, as well as related benzodiazepine and benzocycloheptene, .alpha.v.beta.3 integrin receptor antagonists include WO 96/00574, WO 96/00730, WO 96/06087, WO 96/26190, WO 97/24119, WO 97/24122, WO 97/24124, WO 98/15278, WO 99/05107, WO 99/06049, WO 99/15170, and WO 99/15178, and to Genentech include WO 97/34865. The dibenzocycloheptene, as well as dibenzoxazepine, nucleus has also been employed as a Gly-Asp mimetic to afford .alpha.v.beta.3 antagonists (see WO 97/01540, WO 98/30542, WO 99/11626, and WO 99/15508 all assigned to SmithKline Beecham).

Brief Summary Text (113):

The compounds of the present invention can also be administered in the form of liposome delivery systems, such as small unilamellar vesicles, large unilamellar vesicles and multilamellar vesicles. Liposomes can be formed from a variety of phospholipids, such as cholesterol, stearylamine or phosphatidylcholines.

[Previous Doc](#)[Next Doc](#)[Go to Doc#](#)

[First Hit](#) [Fwd Refs](#)[Previous Doc](#)[Next Doc](#)[Go to Doc#](#)

Generate Collection

Print

L6: Entry 16 of 19

File: USPT

Mar 21, 2000

DOCUMENT-IDENTIFIER: US 6040311 A

TITLE: Integrin receptor antagonists

Brief Summary Text (17):

The .alpha..nu..beta.3 integrin receptor recognizes the Arg-Gly-Asp (RGD) tripeptide sequence in its cognate matrix and cell surface glycoproteins (see J. Samanen, et al., "vascular Indications for Integrin .alpha..nu. Antagonists," Curr. Pharmaceut. Design 3: 545-584(1997)). A benzazepine nucleus has been employed among others by Genentech and SmithKline Beecham as a conformationally constrained Gly-Asp mimetic to elaborate nonpeptide .alpha..nu..beta.3 integrin receptor antagonists substituted at the N-terminus with heterocyclic arginine mimetics (see R. M. Keenan et al., "Discovery of Potent Nonpeptide Vitronectin Receptor (.alpha..nu..beta.3) Antagonists," J. Med. Chem. 40: 2289-2292 (1997); R. M. Keenan et al., "Benzimidazole Derivatives As Arginine Mimetics in 1,4-Benzodiazepine Nonpeptide Vitronectin Receptor (.alpha..nu..beta.3) Antagonists," Bioorg. Med. Chem. Lett. 8: 3165-3170 (1998); and R. M. Keenan et al., "Discovery of an Imidazopyridine-Containing 1,4-Benzodiazepine Nonpeptide Vitronectin Receptor (.alpha..nu..beta.3) Antagonist With Efficacy in a Restenosis Model," Bioorg. Med. Chem. Lett. 8: 3171-3176 (1998). Patents assigned to SmithKline Beecham that disclose such benzazepine, as well as related benzodiazepine and benzocycloheptene, .alpha..nu..beta.3 integrin receptor antagonists include WO 96/00574, WO 96/00730, WO 96/06087, WO 96/26190, WO 97/24119, WO 97/24122, WO 97/24124, WO 98/15278, WO 99/05107, WO 99/06049, WO 99/15170, and WO 99/15178, and to Genentech include WO 97/34865. The dibenzocycloheptene, as well as dibenzoxazepine, nucleus has also been employed as a Gly-Asp mimetic to afford .alpha..nu..beta.3 antagonists (see WO 97/01540, WO 98/30542, WO 99/11626, and WO 99/15508 all assigned to SmithKline Beecham).

Detailed Description Text (82):

The compounds of the present invention can also be administered in the form of liposome delivery systems, such as small unilamellar vesicles, large unilamellar vesicles and multilamellar vesicles. Liposomes can be formed from a variety of phospholipids, such as cholesterol, stearylamine or phosphatidylcholines.

[Previous Doc](#)[Next Doc](#)[Go to Doc#](#)

[First Hit](#)   [Fwd Refs](#)   [Previous Doc](#)   [Next Doc](#)   [Go to Doc#](#)

[Generate Collection](#)[Print](#)

L6: Entry 18 of 19

File: USPT

Feb 7, 1995

DOCUMENT-IDENTIFIER: US 5387600 A

TITLE: Treating arteriosclerosis using benzimidazole compositions[Brief Summary Text](#) (104):2 [Liposome](#)

[Previous Doc](#)   [Next Doc](#)   [Go to Doc#](#)

## Hit List

First Hit

Clear

Generate Collection

Print

Fwd Refs

Bkwd Refs

Generate OACS

Search Results - Record(s) 1 through 19 of 19 returned.

☐ 1. Document ID: US 7056909 B2

L6: Entry 1 of 19

File: USPT

Jun 6, 2006

US-PAT-NO: 7056909

DOCUMENT-IDENTIFIER: US 7056909 B2

TITLE: Alpha v integrin receptor antagonists

DATE-ISSUED: June 6, 2006

PRIOR-PUBLICATION:

DOC-ID

DATE

US 20040038963 A1

February 26, 2004

INVENTOR-INFORMATION:

NAME

CITY

STATE

ZIP CODE

COUNTRY

Wang; Jiabing

Chalfont

PA

US

US-CL-CURRENT: [514/215](#); [514/256](#), [514/274](#), [514/300](#), [514/352](#), [540/580](#), [544/316](#),  
[544/335](#), [546/122](#), [546/311](#), [546/312](#)

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	PubC	Draw D
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	--------

☐ 2. Document ID: US 6962932 B2

L6: Entry 2 of 19

File: USPT

Nov 8, 2005

US-PAT-NO: 6962932

DOCUMENT-IDENTIFIER: US 6962932 B2

TITLE: 1-phenyl-2-heteroaryl-substituted benzimidazole derivatives, their use for the production of pharmaceutical agents as well as pharmaceutical preparations that contain these derivatives

DATE-ISSUED: November 8, 2005

INVENTOR-INFORMATION:

NAME

CITY

STATE

ZIP CODE

COUNTRY

Blume; Thorsten

Schildow

DE

Halfbrodt; Wolfgang

Berlin

DE

Kuhnke; Joachim

Potsdam

DE

Moenning; Ursula	Woltersdorf.	DE
Elger; Bernd	Berlin	DE
Schneider; Herbert	Berlin	DE

US-CL-CURRENT: 514/338; 514/394, 546/273.4, 548/304.7

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	RMIC	Draw D.
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	---------

☐ 3. Document ID: US 6943156 B2

L6: Entry 3 of 19

File: USPT

Sep 13, 2005

US-PAT-NO: 6943156

DOCUMENT-IDENTIFIER: US 6943156 B2

TITLE: Dibenzoxazepine .alpha.v integrin receptor antagonist

DATE-ISSUED: September 13, 2005

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Patane; Michael A.	Andover	MA		

US-CL-CURRENT: 514/211.11; 540/547

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	RMIC	Draw D.
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	---------

☐ 4. Document ID: US 6916810 B2

L6: Entry 4 of 19

File: USPT

Jul 12, 2005

US-PAT-NO: 6916810

DOCUMENT-IDENTIFIER: US 6916810 B2

TITLE: .alpha..nu. integrin receptor antagonists

DATE-ISSUED: July 12, 2005

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Hutchinson; John H.	La Jolla	CA		
Li; Aiwen	West Lake Village	CA		

US-CL-CURRENT: 514/230.5; 514/300, 514/333, 544/105, 544/335, 546/115, 546/118,  
546/122, 546/256, 546/81, 546/82, 548/306.1

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	RMIC	Draw D.
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	---------

☐ 5. Document ID: US 6903126 B2

L6: Entry 5 of 19

File: USPT

Jun 7, 2005

US-PAT-NO: 6903126

DOCUMENT-IDENTIFIER: US 6903126 B2

TITLE: 1-Aryl-2-N-, S- or O-substituted benzimidazole derivatives, their use for the production of pharmaceutical agents as well as pharmaceutical preparations that contain these derivatives

DATE-ISSUED: June 7, 2005

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Blume; Thorsten	Schildow			DE
Halfbrodt; Wolfgang	Berlin			DE
Kuhnke; Joachim	Porsdam			DE
Monning; Ursula	Woltersdorf			DE
Schneider; Herbert	Berlin			DE

US-CL-CURRENT: 514/387; 548/307.1

Full	Title	Citation	Front	Review	Classification	Date	Reference	Abstract	Claims	Index	Drawings
------	-------	----------	-------	--------	----------------	------	-----------	----------	--------	-------	----------

☐ 6. Document ID: US 6855714 B2

L6: Entry 6 of 19

File: USPT

Feb 15, 2005

US-PAT-NO: 6855714

DOCUMENT-IDENTIFIER: US 6855714 B2

TITLE: 1-alkyl-2-aryl-benzimidazole derivatives, their use for the production of pharmaceutical agents as well as pharmaceutical preparations that contain these derivatives

DATE-ISSUED: February 15, 2005

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Blume; Thorsten	Schildow			DE
Halfbrodt; Wolfgang	Berlin			DE
Kuhnke; Joachim	Potsdam			DE
Moenning; Ursula	Woltersdorf			DE
Schneider; Herbert	Berlin			DE
Elger; Bernd	Berlin			DE

US-CL-CURRENT: 514/253.01; 514/234.5, 514/253.09, 514/254.06, 514/394, 544/139, 544/359, 544/364, 544/370, 546/273.4, 548/304.7, 548/306.1, 548/309.7, 548/310.1, 548/310.7

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	RMK	Draw D
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	-----	--------

☐ 7. Document ID: US 6815455 B1

L6: Entry 7 of 19

File: USPT

Nov 9, 2004

US-PAT-NO: 6815455

DOCUMENT-IDENTIFIER: US 6815455 B1

TITLE: Benzimidazole compounds and drugs containing the same

DATE-ISSUED: November 9, 2004

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Aoki; Kozo	Minami-ashigara			JP
Aikawa; Kazuhiro	Minami-ashigara			JP
Kawakami; Masayuki	Minami-ashigara			JP
Yan; Yongzhe	Hiratsuka			JP

US-CL-CURRENT: 514/322; 546/199

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	RMK	Draw D
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	-----	--------

☐ 8. Document ID: US 6787561 B1

L6: Entry 8 of 19

File: USPT

Sep 7, 2004

US-PAT-NO: 6787561

DOCUMENT-IDENTIFIER: US 6787561 B1

TITLE: Benzimidazole compounds

DATE-ISSUED: September 7, 2004

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Aoki; Kozo	Minami-ashigara			JP
Aikawa; Kazuhiro	Minami-ashigara			JP
Kawakami; Masayuki	Minami-ashigara			JP
Yan; Yongzhe	Hiratsuka			JP

US-CL-CURRENT: 514/338; 514/242, 514/255.05, 514/274, 514/312, 514/367, 514/369,  
514/375, 514/381, 514/387, 544/182, 544/298, 544/405, 546/157, 546/273.7, 548/159,  
548/181, 548/221, 548/251, 548/305.4

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	RMK	Draw D
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	-----	--------

☐ 9. Document ID: US 6693101 B2

L6: Entry 9 of 19

File: USPT

Feb 17, 2004

US-PAT-NO: 6693101

DOCUMENT-IDENTIFIER: US 6693101 B2

TITLE: .alpha.v integrin receptor antagonists

DATE-ISSUED: February 17, 2004

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Askew; Ben C.	Newbury Park	CA		
Breslin; Michael J.	Drexel Hill	PA		
Duggan; Mark E.	Schwenksville	PA		
Hutchinson; John H.	Philadelphia	PA		
Meissner; Robert S.	Schwenksville	PA		
Perkins; James J.	Churchville	PA		
Steele; Thomas G.	Schwenksville	PA		
Patane; Michael A.	Billerica	MA		

US-CL-CURRENT: 514/256; 514/212.02, 514/300, 540/521, 540/543, 540/577, 540/580,  
544/316, 544/333, 544/335, 546/115, 546/118, 546/122, 546/123, 546/135

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	FIGS	Drawings
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 10. Document ID: US 6608101 B1

L6: Entry 10 of 19

File: USPT

Aug 19, 2003

US-PAT-NO: 6608101

DOCUMENT-IDENTIFIER: US 6608101 B1

TITLE: 1, 3-bis-(substituted-phenyl)-2-propen-1-ones and their use to treat VCAM-1 mediated disorders

DATE-ISSUED: August 19, 2003

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Ni; Liming	Duluth	GA		
Hoong; Lee K.	Suwanee	GA		
Sikorski; James A.	Alpharetta	GA		
Meng; Charles Q.	Alpharetta	GA		

US-CL-CURRENT: 514/443; 514/438, 549/58, 549/78

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	FIGS	Drawings
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------



☐ 11. Document ID: US 6593323 B1

L6: Entry 11 of 19

File: USPT

Jul 15, 2003

US-PAT-NO: 6593323

DOCUMENT-IDENTIFIER: US 6593323 B1

TITLE: Benzimidazole compounds and drugs containing the same

DATE-ISSUED: July 15, 2003

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Aoki; Kozo	Kanagawa			JP
Aikawa; Kazuhiro	Kanagawa			JP
Kawakami; Masayuki	Kanagawa			JP

US-CL-CURRENT: 514/230.8; 544/139, 546/199, 548/181, 548/226, 548/305.1, 548/306.1

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	FIGS	Drawings
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 12. Document ID: US 6472403 B2

L6: Entry 12 of 19

File: USPT

Oct 29, 2002

US-PAT-NO: 6472403

DOCUMENT-IDENTIFIER: US 6472403 B2

TITLE: .alpha.V integrin receptor antagonists

DATE-ISSUED: October 29, 2002

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Duggan; Mark E.	Schwenksville	PA		
Halczenko; Wasyl	Lansdale	PA		
Hutchinson; John H.	Philadelphia	PA		
Li; Aiwen	Audubon	PA		
Meissner; Robert S.	Schwenksville	PA		
Perkins; James J.	Churchville	PA		
Steele; Thomas G.	Schwenksville	PA		
Wang; Jiabing	Chalfont	PA		
Patane; Michael A.	Billerica	MA		

US-CL-CURRENT: 514/300; 514/212.02, 514/217.01, 514/333, 540/577, 544/105, 544/335, 546/115, 546/118, 546/122, 546/256, 546/81, 546/82, 548/306.1

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	FIGS	Drawings
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 13. Document ID: US 6410526 B1

L6: Entry 13 of 19

File: USPT

Jun 25, 2002

US-PAT-NO: 6410526

DOCUMENT-IDENTIFIER: US 6410526 B1

TITLE: .alpha.v integrin receptor antagonists

DATE-ISSUED: June 25, 2002

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Duggan; Mark E.	Schwenksville	PA		
Hartman; George D.	Lansdale	PA		
Meissner; Robert S.	Schwenksville	PA		
Perkins; James J.	Churchville	PA		

US-CL-CURRENT: 514/212.02; 514/212.06, 514/215, 540/521, 540/543, 540/577, 540/580

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	INOC	Grant D.
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 14. Document ID: US 6358970 B1

L6: Entry 14 of 19

File: USPT

Mar 19, 2002

US-PAT-NO: 6358970

DOCUMENT-IDENTIFIER: US 6358970 B1

TITLE: Integrin receptor antagonists

DATE-ISSUED: March 19, 2002

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Duggan; Mark E.	Schwenksville	PA		
Hartman; George D.	Lansdale	PA		
Perkins; James J.	Churchville	PA		
Ihle; Nathan	Mercer Island	WA		

US-CL-CURRENT: 514/300; 514/253.04, 540/597, 544/362, 546/122

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	INOC	Grant D.
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 15. Document ID: US 6090944 A

L6: Entry 15 of 19

File: USPT

Jul 18, 2000

US-PAT-NO: 6090944

DOCUMENT-IDENTIFIER: US 6090944 A

TITLE: Alkanoic acid derivatives as .alpha.v integrin receptor antagonists

DATE-ISSUED: July 18, 2000

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Hutchinson; John H.	Philadelphia	PA		

US-CL-CURRENT: 546/122; 540/492, 544/284, 546/134, 546/274.4, 546/276.1, 546/277.7, 546/300, 546/4, 548/304.7, 548/323.5, 548/324.5, 548/325.1

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	INDEX	Drawings
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	-------	----------

☐ 16. Document ID: US 6040311 A

L6: Entry 16 of 19

File: USPT

Mar 21, 2000

US-PAT-NO: 6040311

DOCUMENT-IDENTIFIER: US 6040311 A

TITLE: Integrin receptor antagonists

DATE-ISSUED: March 21, 2000

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Duggan; Mark E.	Schwenksville	PA		
Hartman; George D.	Lansdale	PA		

US-CL-CURRENT: 514/275; 514/300, 514/395, 514/398, 544/332, 546/122, 548/308.7, 548/321.5

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	INDEX	Drawings
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	-------	----------

☐ 17. Document ID: US 5962493 A

L6: Entry 17 of 19

File: USPT

Oct 5, 1999

US-PAT-NO: 5962493

DOCUMENT-IDENTIFIER: US 5962493 A

**\*\* See image for Certificate of Correction \*\***

TITLE: 2-mercaptobenzimidazole derivatives and antihyperlipemic agent or antiarteriosclerotic agent containing the same

DATE-ISSUED: October 5, 1999

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
------	------	-------	----------	---------

Aoki; Kozo                      Minami-Ashigara                      JP  
Aikawa; Kazuhiro              Minami-Ashigara                      JP

US-CL-CURRENT: 514/394; 514/395, 514/824

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	IMC	Draw D.
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	-----	---------

☐ 18. Document ID: US 5387600 A

L6: Entry 18 of 19

File: USPT

Feb 7, 1995

US-PAT-NO: 5387600

DOCUMENT-IDENTIFIER: US 5387600 A

TITLE: Treating arteriosclerosis using benzimidazole compositions

DATE-ISSUED: February 7, 1995

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Aikawa; Kazuhiro	Minami-ashigara			JP
Aoki; Kozo	Minami-ashigara			JP

US-CL-CURRENT: 514/395; 514/235.8, 514/237.5, 514/237.8, 514/387, 514/392, 514/394,  
514/396, 514/398, 514/400

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	IMC	Draw D.
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	-----	---------

☐ 19. Document ID: JP 2004115397 A

L6: Entry 19 of 19

File: JPAB

Apr 15, 2004

PUB-NO: JP02004115397A

DOCUMENT-IDENTIFIER: JP 2004115397 A

TITLE: LIPOSOME COMPRISING THERAPEUTIC AGENT FOR VASCULAR DISEASE

PUBN-DATE: April 15, 2004

INVENTOR-INFORMATION:

NAME	COUNTRY
AIKAWA, KAZUHIRO	

INT-CL (IPC): A61 K 9/127; A61 K 31/4184; A61 K 45/00; A61 K 47/24; A61 P 9/00;  
A61 P 9/10; A61 P 43/00

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	IMC	Draw D.
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	-----	---------

Clear

Generate Collection

Print

Fwd Refs

Bkwd Refs

Generate OACS

Terms	Documents
liposome and (\$benzimidazole) same (vascular or arteriosclerosis or atherosclerosis)	19

---

Display Format:

[Previous Page](#)

[Next Page](#)

[Go to Doc#](#)